Showing posts with label Pleural Mesothelioma. Show all posts
Showing posts with label Pleural Mesothelioma. Show all posts

Friday, August 6, 2010

MESOTHELIOMA TREATMENT

MESOTHELIOMA TREATMENT OPTIONS

The treatment program for mesothelioma depends on many factors, including: the stage of the cancer, where the cancer is, how far the cancer has spread, how the cancer cells look under the microscope and the patient’s age and desires.
TIME MATTERS

People diagnosed with this disease are often told the expected survival time is only eight to twelve months. However, specialists in treating malignant mesothelioma at the leading cancer centers often have better statistics.

For instance, the five-year survival rate has approached 40% for selected patients of Dr. David Sugarbaker at Brigham and Women’s Center in Boston. To qualify for Dr. Sugarbaker’s treatment you must meet certain criteria. One of them is being in the early stages of the disease, so time is of the essence. To find out more about Dr. Sugarbaker and other physicians and cancer centers specializing in mesothelioma click on Finding Specialists.

Keeping track of your medical treatment is useful and a personal medical records file can help.


TRADITIONAL CARE



There are three traditional kinds of treatment for patients with malignant mesothelioma:

* Surgery (taking out the cancer)
* Chemotherapy (using drugs to fight the cancer)
* Radiation Therapy (using high-dose x-rays or other high-energy rays to kill cancer cells)

Often two or more of these are combined in the course of treatment. (NEW! Click here for the newest trial of trimodal lung-sparing treatment for pleural mesothelioma: The Columbia Protocol.)


MESOMARK BLOOD TEST

In January 2007, the Food and Drug Administration (FDA) approved the MESOMARK assay to help monitor response to treatment in epithelial and bi-phasic malignant mesothelioma patients. A specific protein, or biomarker, called Soluble Mesothelin-Related Peptide (SMRP), may be released into the blood by mesothelioma cancer cells. By measuring the amount of SMRP in a blood sample, doctors may be able to better monitor a patient's progress. Based on the limited amount of data currently available, use of this test may be beneficial, but effectiveness has not been determined at this time. The MESOMARK blood test has NOT yet been approved for the early diagnosis of mesothelioma.

This test has been approved as a Humanitarian Use Device (HUD), meaning that physicians must follow certain procedures to qualify their patients for testing. Once the physician is certified, informational brochures will be sent to be distributed to each applicable patient.

Those wishing to take part in MESOMARK testing will be asked to provide one or more samples of blood. The blood samples will then be sent to a national reference laboratory for testing. In conjunction with other clinical and laboratory data obtained by your doctor, decisions regarding your treatment and care may be simplified. You may discontinue testing at any time.

The costs associated with the MESOMARK blood test may not be covered under health insurance, therefore, you may be required to pay all or part of the costs out of pocket. It is recommended that you check with your insurance carrier to determine whether coverage is available under your policy.


SURGERY


Diagnostic Procedures

As previously mentioned in the "Symptoms" section of this website, a diagnosis of mesothelioma from fluid is many times inconclusive. Given this fact, diagnostic surgery becomes a necessary next step in confirming and staging mesothelioma.

Thoracoscopy enables a physician to evaluate the pleural cavity and to conduct multiple tissue biopsies under direct vision. In up to 98% of cases, a definitive diagnosis can be obtained. Often, chemical pleurodesis aimed at relieving the accumulation of fluid in the intrapleural space, can be accomplished during the same procedure. It is also possible to gauge the extent of the tumor, and make a determination of surgical resectability. While less invasive than an open biopsy, it can only be performed on patients where tumor has not obliterated the pleural space.

VATS, or video-assisted thoracic surgery is an alternative to thoracoscopy, although because of its more invasive nature, concerns of tumor seeding increase. By utilizing small incisions, the physician can view the pleural space with the assistance of a camera, and obtain sufficient tissue samples for analysis by a pathologist. Extent of the tumor (i.e., pleural involvement, chest wall invasion) may also determined, and recommendation as to the type of debulking procedure necessary can be made at this time.

Mediastinoscopy is sometimes used as an aid in staging extent of disease when enlarged nodes are seen using imaging techniques.

Laproscopy is used in mesothelioma patients in cases where imaging techniques suggest possible invasion of the tumor through the diaphragm. This information can be important in evaluating a patient for potential pleurectomy or extrapleural pneumonectomy.

Palliative Procedures

Palliative surgical procedures are those which treat a symptom of mesothelioma, without aggressively treating the disease itself.

Chest Tube Drainage and Pleurodesis is considered the most common of palliative treatments. Fluid build-up, or pleural effusion, is most often the first symptom which will prompt mesothelioma patients to seek medical attention. Once this effusion has occurred, it is many times persistent, returning rapidly after initial thoracentesis (draining of the fluid). In order to eliminate this problem, the pleural space must be closed. This is accomplished by use of a talc slurry or other sclerosing agent which produces an adhesion.

Thoracoscopy and Pleurodesis is done in conjunction with VATS using a powdered form of talc versus talc slurry. Both this and chest tube drainage and pleurodesis will be only effective if there is no tumor encasing the lung which restricts its expansion.

Pleuroperitoneal Shunt plays a limited role in palliation for several reasons. It involves placement of a catheter run under the skin from the pleural to the peritoneal cavity. Obstruction of the catheter and possible seeding of the tumor into the abdominal cavity may be concerns.

Pleurectomy, used as a palliative procedure, may be performed where more extensive surgery is not an option. In these cases, it is understood that all visible or gross tumor will not be removed. It is considered the most effective means of controlling pleural effusion in cases where the lung's expansion is restricted by disease.

Potentially Curative Procedures

These procedures are performed with "curative intent". Their goal is removal of all gross disease, with the knowledge that microscopic disease will most likely remain. Adjuvant therapy (another form of treatment in addition to the primary therapy) is typically aimed at eliminating residual disease.

For Pleural Mesothelioma:

* Pleurectomy/Decortication is usually performed on patients with early stage disease (Stage I and selected Stage II), and attempts to remove all gross tumor. If it is found that all tumor can not be removed without removing the lung, this may be done at the same time and is called pneumonectomy.
* Extrapleural Pneumonectomy is considerably more radical than other surgical approaches, and should be carried out by surgeons with great expertise in evaluating patients and performing the procedure itself. (See Finding Specialists.) Because in the past surgery alone has failed to effect a cure, or even to help prolong life for any extended period of time, it is currently being combined with traditional chemotherapy and/or radiation, or other new approaches such as gene therapy, immunotherapy or photodynamic therapy.



General Patient Selection Criteria for Extrapleural Pneumonectomy

Extrapleural pneumonectomy is a serious operation, and doctors experienced in this procedure choose their patients carefully. It is up to each individual surgeon to advise the patient on its feasibility and to conduct whatever tests he/she feel are necessary to optimize the patient's chances for survival and recovery. Following is a general list of patient selection criteria. This list may not be all inclusive, and may vary according to the preference of the surgeon.
o Karnofsky Performance Status score of >70. This score relates to what symptoms of disease the patient may be experiencing and how well they are able to conduct their daily activities. Some surgeons may require a higher performance status than others.
o Adequate renal (kidney) and liver function tests; no significant kidney or liver disease.
o Normal cardiac function per electrocardiogram and echocardiography.
o Adequate pulmonary function to tolerate the surgery.
o Disease limited to the ipsilateral hemithorax (the same side of the chest in which the mesothelioma is located) with no penetration of the diaphragm, extension to the heart or extensive involvement of the chest wall.
o Age of the patient is taken into consideration, but may not be as important as their overall status.

Surgeries of this nature should always be done with a complete understanding of the possible benefits and risks involved. If you are considering surgery as a treatment option, speak openly with your doctor about your concerns, and be sure all of your questions are answered to your satisfaction.



For Peritoneal Mesothelioma:

* Cytoreductive Surgery is aimed at removing all or nearly all of the gross or visible tumor in the peritoneal cavity. In order to treat any remaining cancer cells, Intra-Peritoneal Hyperthermic (heated) Chemotherapy (IPHC) is then delivered to the abdominal cavity. The type of chemotherapy drug used may vary according to the physician’s preference. Click here for more on treatment of peritoneal mesothelioma.

TOP

CHEMOTHERAPY


Chemotherapy is defined as the treatment of cancer using chemical substances. When cancer occurs, abnormal cells continue to divide uncontrolled. Anticancer, or chemotherapy drugs, work to destroy cancer cells by preventing them from multiplying.

Purposes of Chemotherapy

Chemotherapy may be used to achieve different goals, depending on the stage of the cancer at the time of diagnosis and the age and health of the patient. Since chemotherapy for mesothelioma is not considered "curative", the goal is:

* To control the cancer by stopping its spread or slowing its growth.
* To shrink tumors prior to other treatments, such as surgery. This is called neoadjuvant chemotherapy.
* To destroy microscopic disease which may remain after surgery. This is called adjuvant chemotherapy.
* To relieve symptoms, such as pain. This is called palliative chemotherapy, and is given in cases when a drastic reduction in the tumor is not expected.

The most common use for chemotherapy in mesothelioma patients, is as an option for those who are not surgical candidates, however, cancer centers are conducting trials using the neoadjuvant approach (giving chemotherapy before surgery). Alimta (pemetrexed) is a drug approved by the Food and Drug Administration (FDA) for use with Cisplatin in the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are not candidates for curative surgery. Alimta is the first drug approval specific to mesothelioma.

The Alimta/Cisplatin chemotherapy regimen is the first Food and Drug Administration (FDA) approved treatment specifically for malignant pleural mesothelioma. This is currently considered the most effective first-line treatment for mesothelioma patients who are not surgical candidates. A multi-targeted antifolate drug, Alimta works by blocking the enzymes necessary for DNA copying and cell division. During the clinical trial process, Alimta/Cisplatin improved median survival for pleural mesothelioma patients by approximately three months over treatment with Cisplatin as a single agent.

As with any medical treatment, it is important to discuss the use of Alimta with your doctor. This conversation should include all pertinent information regarding effectiveness, administration and possible side effects of the drug combination. It is also important to begin vitamin supplementation of B12 by injection during the week prior to treatment (to be repeated every 9 weeks), and folic acid by mouth daily (to be continued until 21 days after the last cycle of Alimta). Additionally, you will be given an oral steroid medication to minimize the risk of skin rash or other possible side effects. Your doctor will have information on the correct dosages of each medication. Be sure to tell your doctor of any other medications you are taking (including non-prescription drugs) so he may be aware of any adverse interactions.

Alimta/Cisplatin is administered to patients on an outpatient basis every 21 days. This cycle of treatment consists of a 10-minute IV infusion of Alimta followed by a 2-hour infusion of Cisplatin. How many cycles of treatment you receive depends on your response to the drug (regression of the tumor or halt to progression of the disease) and the side effects you might experience.

Side effects of Alimta/Cisplatin are mild to moderate for most mesothelioma patients, i.e., nausea, vomiting and fatigue, and can usually be managed by your doctor. For some patients, however, side effects may be debilitating, and may require a decrease in dosage or removal from the program. All potential side effects should be mentioned to your doctor. Never assume any complaint is minor.

Administration of Chemotherapy

The most common way to administer chemotherapy is intravenously, or through a vein. A thin needle is inserted into a vein in the hand or in the lower arm. Intravenous administration of drugs allows for rapid entry into the blood stream. Drugs may also be delivered via catheters and/or ports.

* Catheters are soft, thin, flexible tubes placed into a large vein in the body. They remain in place for as long as they are needed.
* The catheter may sometimes be attached to a port, a small round plastic or metal disc placed under the skin on the chest. Ports also remain in place for as long as necessary.

Intraperitoneal chemotherapy may also be delivered through a catheter or a port. The catheter is inserted through the abdominal wall. Chemotherapy drugs can then be infused directly into the abdominal cavity for treatment of peritoneal mesothelioma. Ports may also be placed under the skin of the abdominal wall and the catheter tunneled between the skin and muscle into the peritoneum.

Frequently asked questions about being a chemotherapy patient.

Side Effects of Chemotherapy

Cancer cells grow and divide more rapidly than normal cells, but some normal cells also multiply quickly, particularly those in the digestive tract, reproduction system, and hair follicles. It is the damage done to normal cells that causes side effects. The type of side effects you might experience and how severe they are, depend on the type of chemotherapy you are receiving, the dosage given and how your own body reacts. Before beginning any chemotherapy treatment, you will be asked to sign a consent form. Before signing the form, be sure your doctor informs you of all the facts regarding the treatment he/she will be administering, including information about the particular drug or combination of drugs to be used, the possible risks or side effects (including nausea and vomiting and peripheral neuropathy), the number of treatments you will receive and how often, and whether it will be given during a hospital stay or on an outpatient basis. More on vomiting and nausea from chemotherapy. More on peripheral neuropathy. More on anti-nausea treatment for chemotherapy patients.

Click here if you are interested in learning more about chemotherapy for mesothelioma and the types of questions you should ask your doctor.


Chemotherapy Schedules

How often you will receive chemotherapy will be determined by your doctor, taking into consideration factors such as the stage of your cancer, the types of drugs you receive, the anticipated toxicities of the drugs and the time necessary for your body to recover from these toxicities. The doctor may also consider whether the goal of the chemotherapy is to control the growth of the cancer, or to ease symptoms associated with the disease.

In general, chemotherapy treatment is administered in "cycles" — a "cycle" being defined as a period of treatment followed by a period of rest. This cycle allows the cancer cells to be attacked by the drugs, and then allows the body's normal cells time to recover. The combination of drugs used, the length of time to administer the drugs, how often they should be repeated and the number of cycles recommended have been analyzed throughly in clinical trials. For mesothelioma patients, the "standard" treatment is a combination of Alimta and cisplatin, administered IV, with a 10 minute infusion of Alimta followed by two hours of cisplatin, given in 21 day cycles. Modifications to this schedule may be made according to what your doctor feels is appropriate in your particular case.

The number of treatment cycles, or the length of time between the beginning and end of chemotherapy may vary, however in general, 3 to 4 cycles of treatment are given before response is evaluated; 2 to 3 cycles are considered a minimum to assess for effectiveness. After response to the treatment has been determined, the following criteria will be used to decide whether chemotherapy should continue:

* If there is shrinkage of the tumor, or the disease is kept stable, chemotherapy may be continued for as long as it can be tolerated and there is no disease progression.
* If there is continued disease progression, chemotherapy will be stopped, and the patient will be given alternative options.

The goal of setting a chemotherapy schedule is to make treatment as effective, timely and trouble-free as possible, but while the drugs are working to kill cancer cells, they may also affect healthy cells causing side effects. One of the most common side effects, and one your doctor will monitor carefully, is a chemotherapy-induced low white blood cell count (neutropenia) which means your immune system is weakened, therefore leaving you more prone to infection. While this side effect is anticipated when someone is undergoing chemotherapy, it can cause delays in your treatment schedule, or changes in the dosage of the drugs you will receive. Click here for more on understanding your blood counts.

TOP

Note to Patients:

Chemotherapy treatment should be a cooperative effort between you and your doctor. The interaction that takes place is important to your health. It will not only help you feel better, but will also address any potential problems with miscommunication.

1. It is necessary for your doctor to be aware of any side effects which may result from your chemotherapy treatment.
These may include:
* Fever of, or greater than 101 degrees
* Nausea or vomiting
* Diarrhea or constipation
* Fatigue
* Tingling or numbness in the fingers or toes
* Ringing in the ears
* Bruises or rashes
* Sores in the mouth or throat
2. Taking other medication of any kind can alter the effects of chemotherapy or cause undesirable interactions.
Be sure you report all over-the-counter and prescribed medicines to your doctor. Don’t take aspirin unless it has been approved by your doctor. Ask your pharmacist if aspirin is contained in any drugs you plan to purchase.
3. Take extra care with your daily health.
Try to maintain a stable weight by eating a healthy diet and drinking plenty of fluids. If your stomach is upset, ask your doctor for helpful hints or work with a nutritionist who can tailor a program to your needs. Brush your teeth after every meal, or if you can’t brush, rinse your mouth thoroughly with water.

Stay away from people who have colds or the flu. Chemotherapy can compromise your immune system and lower your resistance to germs. Make sure you keep appointments for blood work – these tests help your doctor monitor your health.


4. Be open about your feelings regarding your treatment.
It is normal to feel sad, angry or afraid, however, letting these emotions get out of control can be detrimental to your overall well-being. Seek out the help of family, friends, your doctor, a counselor or a support group.





RADIATION THERAPY

Radiation therapy, also called radiotherapy, treats cancer by using penetrating beams of high energy or streams of particles called radiation. In treating mesothelioma, radiation may be used aggressively in combination with surgery, or palliatively to control symptoms.

In an aggressive combined modality approach, radiation is used to attack microscopic or residual disease remaining in the chest cavity after extrapleural pnuemonectomy. An example of this is Intensity Modulated Radiation Therapy (IMRT), which uses x-rays of varying intensities in conjunction with computer generated images to deliver targeted radiation directly to cancer cells while reducing the amount of radiation to surrounding healthy tissue. More on Intensity Modulated Radiation Therapy (IMRT).

Used palliatively, radiation can help control metastases (spread) of the tumor along tracks left by invasive procedures such as thoracoscopy, needle biopsy and chest tube drainage, or to control disease symptoms, such as pain or shortness of breath.

An exciting new development in radiation oncology is tomotherapy. A brief description of steps in the helical tomotherapy process.

Friday, July 30, 2010

PLEURAL MESOTHELIOMA

Welcome to the Pleural Mesothelioma

Part of our mission at PleuralMesothelioma.com is to provide current, reliable data on all topics relating to pleural mesothelioma cancer. We are dedicated to compiling the latest and most up-to-date information on pleural mesothelioma and offer a number of resources to those coping with the pulmonary cancer. From treatment options to top doctors and the best cancer centers in the United States, PleuralMesothelioma.com is a one-stop resource for pleural mesothelioma patients and their families.
The Next Step: Life After a Pleural Mesothelioma Diagnosis

After a patient has been diagnosed with pleural mesothelioma, one of the first concerns for a patient and their family will be available treatment options to improve prognosis. The following include important topics for recently diagnosed pleural mesothelioma patients.


Improving Pleural Mesothelioma Life Expectancy

While prognosis for pleural mesothelioma patients typically ranges between four and 18 months, there are several traditional and alternative treatment methods that may prolong a patient’s life expectancy. Some prognostic factors cannot be changed, but improving patient heath and treatment efforts, quitting smoking, and the addition of immune-boosting therapies are a few ways to potentially improve a patient’s life expectancy.
Pleural Mesothelioma Diagnosis and Treatment

Receiving an official pleural mesothelioma diagnosis often comes after a series of imaging tests, collection of fluid samples and a tissue sample known as a biopsy. The stage of development the cancer has reached by the time of diagnosis has a great impact on available pleural mesothelioma treatment options.

Pleural Mesothelioma Causes

Exposure to asbestos is the primary cause of pleural mesothelioma. Used in many industries throughout the 20th century, asbestos was found in thousands of products and those who worked with the material in an occupational setting are most at risk for developing pleural mesothelioma. Pleural mesothelioma research is exploring other risk factors, but none have been proven like the link between asbestos and pleural mesothelioma.
Pleural Mesothelioma and Veterans

As a result of their exposure during military service, U.S. veterans account for a sizable percentage of pleural mesothelioma patients. The group of veterans most at risk is naval veterans and this is a result of the mass amount of asbestos material used on naval vessels. Navy veterans who worked in shipyards or aboard vessels experienced more asbestos exposure than the average member of the Armed Forces and can claim benefits from the VA system for this service-related condition.
More Resources

Sunday, January 27, 2008

Asbestos victims’ drug hope

VICTIMS of York's asbestos timebomb have been given a major boost after a medicine rationing organisation ruled they are entitled to a vital drug.

The National Institute for Clinical Excellence (NICE) has decided the drug Alimta should be made available to patients with the asbestos-related cancer mesothelioma.

The York Asbestos Support Group today hailed the decision, saying that while the drug was not a cure, it could both extend life and alleviate symptoms for patients and was the only treatment available.

"The NICE decision brings to a conclusion an approval process which started almost three years ago and which led to one of the worst examples of the health postcode lottery," said the group's delighted founder Kim Daniells.

"Hundreds of patients across the UK were refused treatment with this drug whilst those in Scotland, the North West and North East of England could access treatment."

She said NICE had rejected an appeal against an original decision to approve the use of the drug for the treatment of the condition, which was a fatal tumour of the lung pleura caused by exposure to asbestos.

"In the last three years, many hundreds of patients have been diagnosed with the condition and gone on to die without ever being able to access the treatment. Hopefully this situation will now come to an end."

She said NICE's guidance meant primary care trusts would now be obliged to provide uniform treatment.

They would be given the option of a 90-day lead-in period following the official announcement, but she hoped the guidance would result in mesothelioma sufferers gaining prompt access to the treatment they needed and deserved.

The decision could benefit former York Carriageworks employees who fall victim in future to mesothelioma.

Staff were widely exposed to deadly asbestos dust fibres during the 1950s, 1960s and 1970s, and even in the 1980s after some measures had been brought in to provide protection to staff.

Scores of ex-workers have died from the devastating cancer.

A NICE spokesman said Alimta was being recommended as a possible treatment for malignant pleural mesothelioma in people with advanced disease, and whose cancer was not suitable for surgical removal and who met certain other conditions.

Source

Wednesday, January 23, 2008

Alfacell Signs Onconase Purchase And Supply Deal With Scientific Protein Labs [ACEL]

(ACEL) announced that it has entered into a purchase and supply agreement with Scientific Protein Laboratories LLC or SPL for the commercial production of Onconase or ranpirnase.

Onconase, the company's lead drug candidate, is currently being evaluated as a treatment for unresectable malignant mesothelioma or UMM in a confirmatory Phase IIIb clinical trial.

Kuslima Shogen, chief executive officer of Alfacell, said, “We have been pleased with the superb performance of the extremely well qualified team at SPL for many years and are confident that the commercial production of ONCONASE is in the right hands. This agreement is another step forward for Alfacell as we plan for the commercialization of ONCONASE.”

Onconase is a first-in-class product candidate from Alfacell's proprietary ribonuclease or RNase technology.

In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of Onconase in non-small cell lung cancer or NSCLC and other solid tumors.

ACEL is currently trading at $2.40, up 16 cents or 6.95%.

Source

Thursday, December 13, 2007

PLEURAL MESOTHELIOMA PROGNOSIS

The prognosis of mesothelioma refers to the possible outcome of mesothelioma. Malignant pleural mesothelioma is a lethal disease and little is known about prognostic factors. A few have survived as long as 5 years, with rates of 14% for all types and 46% for the epithelial type. However, there are long term pleural mesothelioma survivors who have survived more than 10 years (although very rare).

In a recent mesothelioma study, doctors writing about the prognosis of pleural mesothelioma explained that long-term mesothelioma survivors do exist and their prognosis may be independent of the treatment or therapies used.

Age, stage of disease, gender and histological subtype are factors that are considered when prognosis of pleural mesothelioma is being carried on. With trimodality treatment, some patients have survived 16-19 months. However, numbers are small. Despite a ban on asbestos (major cause) use in Western countries, the incidence of malignant pleural mesothelioma is increasing, due to the long delay between asbestos exposure and diagnosis.

Moreover, asbestos is still used in developing countries.Without treatment, mesothelioma is fatal within 4-8 months.

Wednesday, December 12, 2007

PLEURAL MESOTHELIOMA DIAGNOSIS

Presently there seems to be no cure for mesothelioma, but its early diagnosis can provide doctors the opportunity to relieve the patients of a great deal of suffering, and prolong their lives thus improving their general health outlook। These treatment options depend on the stage and the overall progession of the disease. The pleural form of mesothelioma, which represents more than 90% of all cases, presents on x-ray as diffuse unilateral or bilateral pleural thickening that appears to encase the lungs, usually producing blunting of the costophrenic angles. Pleural effusions are present in 95% of cases and are typically unilateral, massive effusions.





Diagnosis is majorly based on pleural fluid cytology or open pleural biopsy and, if these are nondiagnostic, biopsy by video-assisted thorascopic surgery (VATS) or thoracotomy is used.
Staging is done with chest CT, mediastinoscopy, and MRI. Sensitivity and specificity of MRI and CT are comparable, although MRI is helpful in determining tumor extension into the spine or spinal cord. PET may have better sensitivity and specificity for distinguishing benign from malignant pleural thickening.
Using Bronchoscopy rules out coexisting endobronchial malignancies। Increased hyaluronidase levels in pleural fluid are suggestive but not diagnostic of disease. Soluble mesothelin-related proteins released into the serum by mesothelial cells are being studied as possible tumor markers for disease detection and monitoring.


Mesothelioma स्टील remains an incurable cancer.

Monday, December 10, 2007

SYMPTOMS OF PLEURAL MESOTHELIOMA

Pleural mesothelioma is a disease whose symptoms are not easily noticeable. Although at the early stages of the disease patients do complain of recurring heart and chest pains.



Generally the symptoms are always mild at the initial stages but do get serious and complicated as soon as it reaches its matured that is when it becomes visible. Chest pain is the most common. Other symptoms include; coughs, weight loss and anorexia. Others are persistent coughing, difficulty in swallowing, facial swelling, weight loss, fever, rasping, and coughing up blood.



In some cases patients do complain of shortness of breath. This is as a result of the thickening of the pleura as the tumour begins to spread. This makes it to be filled with fluid. This fluid leads to the discomfort or pain associated with first detection of the disease.



Pleural mesothelioma patients display all three types of mesothelioma cancer cells: epithelioid mesothelioma, sarcomatoid mesothelioma and biphasic mesothelioma

PLEURAL MESOTHELIOMA

When the famous Australian anti-racism activist Bob Bellear died in 2005 of mesothelioma, not until then did the disease started becoming popular. Mesothelioma occurs in different forms of which pleural mesothelioma is one.

Pleura mesothelioma is a form of mesothelioma that occurs around the lungs and respiratory area of the chest region. It attacks the cell and the linings of the lungs which are known as the pleura, hence the name pleura.





It do start from the lungs and in some cases spread to other parts of the body including the brain thereby causing more damage than not





Sometimes it occur in two forms- benign (non-cancerous) and malignant (cancerous) but malignant is the most common of the two.
It is the most common form of mestheolima, 7-8 out of every 10 cases of mesothelioma cases are mesothelioma of the pleura. Due to the nature of this disease it might take 30-50years before the symptoms start to surface after being exposed to asbestos. This makes the disease not to be known until when it is too late.

Thursday, December 6, 2007

TYPES OR FORMS OF MESOTHELIOMA CANCER

The type of mesothelioma is determined on the basis where the cancer occurs in the body. Mesothelioma may affect any part or organ of the body depending on the level of exposure to asbestos and the time level over which the patient has been exposed to.
The major types of mesthelioma cancer includes the following;

* Pleural Mesothelioma

*Peritoneal Mesothelioma

* Pericardial Mesothelioma

Pleural Mesothelioma

Pleural mesothelioma, also known as mesothelioma of the pleura is a tumour in which the lining of the lungs, or lung pleura, gets affected by malignant cells. It is one of the most commonly occurring cancers. The pleura is a thin tissue around the lungs and the inside of the chest.
It helps the lungs in breathing (respiration) by producing a serous fluid that lubricates the pleural surfaces to avoid the teasing of the lungs against the chest wall. In order to protect the lungs, the pleura produces a small amount of fluid which helps cushion the lungs, making the lungs move more smoothly during breathing.

Types of pleural mesothelioma cancer

Diffused or Malignant (Cancerous) MESOTHELIOMA

Malignant Pleural mesothelioma is cancerous and can spread to other parts of the body. This rare form of cancer is found in the pleural sac lining of the lung. Exposure to asbestos is considered the primary cause of pleural mesothelioma.

Benign (Non-Cancerous) pleural mesothelioma

This is the non-cancerous form of pleural mesothelioma, which does not affect all parts of the body but the pleura. However, it constricts the lung causing shortness of breath, and in some severe cases, pneumothorax (lung failure)

Peritoneal mesothelioma

This is the next common type of mesothelioma which affects peritonium which is the lining of the abdominal cavity including the stomach. It is more aggressive than the mesothelioma of the pleura. Its symptoms include the following chest pain, anaemia, breathlessness, loss of appetite and other severe symptoms. It could either be malignant (cancerous) or benign (non-cancerous). Their is a high probability of women being diagnosed with peritoneal mesothelioma than other types of mesothelioma.

Pericardial mesothelioma

This is the rarest and least but deadliest type of mesothelioma because it affects the heart and the cavity surrounding it. It is said to have an average lifespan of less than six months from diagnosis. Due to the rarity of this disease as many patients are ignorant of the presence of this disease in their body until diagnosis is made on their autopsies, it makes it difficult for doctors and researchers to understand the whole logic behind the nature of this disease.

Symptoms might include congestive heart failure, palpitation, night sweat, persistent cough, chest pain and breathing disorder. Pericardial mesothelioma can sometimes be palpatively treated through surgery and further treatment of radiation and chemotherapy.

Every year about 2,000 new cases of mesothelioma are being diagnosed, and the figure might still be increasing. The major cause of mesothelioma has been linked to asbestos inhaling due to being exposed to it. So watch out next time you are out in mining area.

Monday, November 12, 2007

Asbestos Exposure only Known Link to Pleural Mesothelioma

Los Angeles, CA: Even though asbestos has been a dirty word for decades, and its use and prevalence has dramatically declined, the toxic substance is still making its presence felt, and is still at the root cause of serious health problems including pleural mesothelioma. In many cases it is claiming lives.

Walter Kot of Illinois is just the latest worker to file a lawsuit against a host of corporations he claims were negligent in their responsibility to inform workers about the presence of asbestos and ways in which, through hygiene and other practises, to mitigate its spread and prevalence.

Kot is upset that on numerous occasions he transported, unknowingly, asbestos fibres home.
Kot toiled as a labourer, sheet-metal worker, shipper, forester and firefighter at the behest of a number of companies from 1940 through 1980. This past July he was diagnosed with mesothelioma, and is litigating a total of 49 corporations for damages and compensation, which will ultimately help cover his medical bills.

In his lawsuit, filed last week in Madison County, Kot claims that the defendants should have known about the hazards of asbestos, and should have been more diligent in protecting its employees from needless exposure.

The suit also alleges that the various defendants could have used asbestos substitutes in their products, but did not.

It has also been alleged that some, or all of the defendants - which were not named publicly - may have destroyed documents and certain evidence, which would have proven Kot's claims.

As a result Kot is seeking at least $550,000 in compensatory damages for pain and suffering, and lost wages. He is also seeking punitive damages representing an undisclosed sum.

Meanwhile, a navy sailor last week was awarded $35.1 million in compensatory damages for exposure to asbestos while serving more than fifty years ago.

John R. 'Jack' Davis was diagnosed, like Kot, with pleural mesothelioma - a disease linked to asbestos exposure. In his suit, Davis claimed that he was exposed to asbestos-covered pipes and vales during his tour of duty in the U.S. Navy, as well as his private-sector career.

The Navy, along with a number of un-named defendants, will have to pool in order to pay the lion's share of the award, 85.8 per cent. The remaining 14.2 per cent of the award is the responsibility of Leslie Controls of Florida, and Warren Pumps of Massachusetts, which will each pay 7.1 per cent. The latter two companies were identified as having supplied asbestos-based material to the Navy.

The verdict, delivered by a jury in Los Angeles Superior Court after a five-week trial, came after deliberations of less than a day, and breaks down to $100,000 for economic damages, $25 million for Mr. Davis' pain and suffering, and a further $10 million for his wife.

Pleural mesothelioma is a deadly cancer that is linked exclusively to the inhalation of asbestos particles in the air. Various countries have implemented an outright ban of asbestos use, something the United States tried but failed, after the ban was overturned in the courts. As a result, there are still products which contain asbestos, such as brake linings.

The incubation period is a long one: the lag time between asbestos exposure and the onset of pleural mesothelioma can be anywhere from 20 to 50 years.

Little wonder that Mr. Kot and Mr. Davis, identified above, litigated so long after exposure. Both men were diagnosed in 2007, decades after the fact.

It is a reasonable expectation there will be many more to come.

SOURCE

'Cruel injustice' of axed asbestos pay-outs

FAMILIES and campaigners yesterday condemned the "injustice" of a House of Lords ruling which will end compensation for thousands of workers suffering from an asbestos- related condition.

The judgment removes an established right to compensation, which had existed for 20 years, to allow people with pleural plaques - scars on the lungs - to claim damages.

Those affected claim these scars can develop into more serious conditions including cancer. However, their longstanding right to compensation was subject to an appeal by insurance companies, with the Court of Appeal finding in the companies' favour last year that pleural plaques was not a disease.

Unions appealed this and the controversial case went before the Lords yesterday, where the Court of Appeal decision was upheld.

The five Law Lords who heard the cases agreed that the appeals should be dismissed because the law does not offer compensation to victims of injuries which cause no or trivial damage.

Activists have now pledged to ask the Scottish Parliament to bring in new legislation in Scotland to reverse the Lords' judgment.

They have prepared a bill, which has cross-party support, and will submit it to Kenny MacAskill, the justice secretary, urging him to change the law north of the Border.

Harry McCluskey, secretary of Clydeside Action on Asbestos, which represents hundreds of families of former shipyard and factory workers, said: "The judgment has gone against the workers who have to live with the condition with the appalling fear that it could develop into mesothelioma [a form of cancer].

"It is a ridiculous judgment and the injustice is cruel."

Ian Tasker, of the STUC, said: "The STUC has supported asbestos groups and we are extremely disappointed that this is another injustice to the victims of asbestos.

"The legal system pays too much attention to business and it doesn't pay enough attention to the victims."

Pleural plaques can, over time, make breathing difficult and, in some cases, can be accompanied by the development of serious respiratory diseases including mesothelioma and lung cancer.

Previously, victims could claim between £6,000 to £10,000 if they had pleural plaques and more if they developed mesothelioma.

Bill Kidd, an SNP MSP and Robert Brown, a Liberal Democrat MSP, backed the move to introduce new legislation at the Scottish Parliament.

Mr Kidd said: "This decision by the House of Lords flies in the face of common sense and has to be rectified as quickly as possible."

Bill Butler, a Labour MSP, added: "[The ruling] comes down on the side of the employers and insurance companies and disregards the legitimate case of victims and their families."

Solicitor-advocate Frank Maguire, of Thompsons Solicitors, a leading campaigner for asbestos victims, said: "This judgment will only diminish respect for the law by showing how divorced it can be from reality."

SOURCE

LinkWithin